These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

472 related items for PubMed ID: 17609428

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Identification of a leukemia-initiating stem cell in human mast cell leukemia.
    Eisenwort G, Sadovnik I, Schwaab J, Jawhar M, Keller A, Stefanzl G, Berger D, Blatt K, Hoermann G, Bilban M, Willmann M, Winding C, Sperr WR, Arock M, Rülicke T, Reiter A, Valent P.
    Leukemia; 2019 Nov; 33(11):2673-2684. PubMed ID: 30953030
    [Abstract] [Full Text] [Related]

  • 23. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.
    Herrmann H, Sadovnik I, Eisenwort G, Rülicke T, Blatt K, Herndlhofer S, Willmann M, Stefanzl G, Baumgartner S, Greiner G, Schulenburg A, Mueller N, Rabitsch W, Bilban M, Hoermann G, Streubel B, Vallera DA, Sperr WR, Valent P.
    Blood Adv; 2020 Oct 27; 4(20):5118-5132. PubMed ID: 33085758
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients.
    Ngai LL, Ma CY, Maguire O, Do AD, Robert A, Logan AC, Griffiths EA, Nemeth MJ, Green C, Pourmohamad T, van Kuijk BJ, Snel AN, Kwidama ZW, Venniker-Punt B, Cooper J, Manz MG, Gjertsen BT, Smit L, Ossenkoppele GJ, Janssen JJWM, Cloos J, Sumiyoshi T.
    Eur J Haematol; 2021 Sep 27; 107(3):343-353. PubMed ID: 34053123
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34+/CD38+ and CD34+/CD38- AML progenitor cells.
    Herrmann H, Kneidinger M, Cerny-Reiterer S, Rülicke T, Willmann M, Gleixner KV, Blatt K, Hörmann G, Peter B, Samorapoompichit P, Pickl W, Bharate GY, Mayerhofer M, Sperr WR, Maeda H, Valent P.
    Curr Cancer Drug Targets; 2012 Jan 27; 12(1):51-63. PubMed ID: 22165967
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. FISH+CD34+CD38- cells detected in newly diagnosed acute myeloid leukemia patients can predict the clinical outcome.
    Wang L, Gao L, Xu S, Gong S, Chen L, Lü S, Chen J, Qiu H, Xu X, Ni X, Song X, Zhang W, Yang J, Liu M, Hu X, Wang J.
    J Hematol Oncol; 2013 Nov 07; 6(1):85. PubMed ID: 24517186
    [Abstract] [Full Text] [Related]

  • 30. Phenotyping and Target Expression Profiling of CD34+/CD38- and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia.
    Blatt K, Menzl I, Eisenwort G, Cerny-Reiterer S, Herrmann H, Herndlhofer S, Stefanzl G, Sadovnik I, Berger D, Keller A, Hauswirth A, Hoermann G, Willmann M, Rülicke T, Sill H, Sperr WR, Mannhalter C, Melo JV, Jäger U, Sexl V, Valent P.
    Neoplasia; 2018 Jun 07; 20(6):632-642. PubMed ID: 29772458
    [Abstract] [Full Text] [Related]

  • 31. A CD38-directed, single-chain T-cell engager targets leukemia stem cells through IFN-γ-induced CD38 expression.
    Murtadha M, Park M, Zhu Y, Caserta E, Napolitano O, Tandoh T, Moloudizargari M, Pozhitkov A, Singer M, Dona AA, Vahed H, Gonzalez A, Ly K, Ouyang C, Sanchez JF, Nigam L, Duplan A, Chowdhury A, Ghoda L, Li L, Zhang B, Krishnan A, Marcucci G, Williams JC, Pichiorri F.
    Blood; 2024 Apr 18; 143(16):1599-1615. PubMed ID: 38394668
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Targeting of CD34+CD38- cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in Acute Myeloid Leukaemia.
    Jawad M, Yu N, Seedhouse C, Tandon K, Russell NH, Pallis M.
    BMC Cancer; 2012 Sep 26; 12():431. PubMed ID: 23013471
    [Abstract] [Full Text] [Related]

  • 35. Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2.
    Xu B, Wang S, Li R, Chen K, He L, Deng M, Kannappan V, Zha J, Dong H, Wang W.
    Cell Death Dis; 2017 May 18; 8(5):e2797. PubMed ID: 28518151
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia.
    Zeijlemaker W, Kelder A, Cloos J, Schuurhuis GJ.
    Curr Protoc Cytom; 2019 Dec 18; 91(1):e66. PubMed ID: 31763792
    [Abstract] [Full Text] [Related]

  • 38. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia.
    Bakker AB, van den Oudenrijn S, Bakker AQ, Feller N, van Meijer M, Bia JA, Jongeneelen MA, Visser TJ, Bijl N, Geuijen CA, Marissen WE, Radosevic K, Throsby M, Schuurhuis GJ, Ossenkoppele GJ, de Kruif J, Goudsmit J, Kruisbeek AM.
    Cancer Res; 2004 Nov 15; 64(22):8443-50. PubMed ID: 15548716
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0): reduced immunogenicity and high frequency of CD34+/CD38- leukemic progenitors.
    Costello R, Mallet F, Chambost H, Sainty D, Arnoulet C, Gastaut JA, Olive D.
    Leukemia; 1999 Oct 15; 13(10):1513-8. PubMed ID: 10516751
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.